Scientists Get Authorization To Play God


An incredible innovative medical trial (pioneered by a US Biotech company) that aims at testing how possible it will be to regenerate the brains of dead people has received the go-ahead signal from health authorities.

The groundbreaking idea came from a US biotech company which has been granted the necessary ethical permission to recruit 20 patients who have been confirmed clinically dead as a result of a traumatic brain injury.

See Also: 9 Babies Exposed To Danger In Possible Outbreak Of Klebsiella Infection In KZN

The company’s scientists will then use the test subjects to test the possibility of bringing back to life all parts of their central nervous systems. Scientists at the trial will combine a lot of therapies and also exploit both lasers and nerve stimulation techniques that have been tested and proven to bring patients out of a comatose condition.

The patients that will be used in this trial will have been certified dead but will however be kept alive through life support before the trial will commence. The trial will involve close monitoring using the brain imaging equipment which will linger for several months. This is to enable scientists search for possible signs of regeneration, with more reference to the upper spinal cord.

The team also believes that some processes seen in the animal kingdom – in some creatures like the salamander, known to regrow its entire limbs – also can be applicable to humans too.

See Also: South African “No-Fee School” Receives Science Equipment From Online Readers

They believe that based on the tissues surrounding them, the brain stem cells might be able to bounce back from whatever damage they must have suffered and start life afresh.

This is really one of a kind as confirmed by the chief executive of Bioquark Inc Ira Pastor.

“This represents the first trial of its kind and another step towards the eventual reversal of death in our lifetime. We hope to see results within the first two to three months.”

Like BuzzSouthAfrica: